CAR-T cell therapy for high-risk plasma cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your caregiver must agree to the study rules and sign a consent form.
- You have high-risk plasma cell cancer (like certain chromosome changes or high levels of a protein called beta-2 microglobulin).
- You are between 18 and 75 years old.
- You are still active and able to care for yourself (ECOG score 0-2).
- Your vital organs (heart, lungs, kidneys, liver) work well enough, and your blood counts are adequate.
- You are not pregnant or breastfeeding, and you agree to use effective birth control for one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment that targets both CD19 and BCMA proteins on cancer cells. It may help people with multiple myeloma, plasma cell leukemia, or related cancers that have not responded to at least three prior treatments.
This trial tests a new type of CAR-T cell therapy that targets two markers (CD19 and BCMA) on cancer cells. It is for people with certain blood cancers like multiple myeloma or lymphoma that have not responded to other treatments.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
Hear when a new High-risk Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.